Overview
Mynd Therapeutics develops next-generation psychedelic-derived compounds targeting treatment-resistant depression and PTSD through precision neurochemistry.
More in Neuropharmaceuticals
Latest industry news
Wearable Neurofeedback Startup BRYM Secures €650K to Build Next-Generation Brain Training Platform
2026-10-24 · Funding
Brain-Computer Interface Gives Unresponsive ICU Patients Auditory Control for the First Time
2026-10-23 · Research
China Moves to Standardise Brain-Computer Interface Technology, Reshaping Global Neurotech Governance
2026-10-22 · Policy
BCI Market Projected to Sustain 17.9% CAGR Through 2033 as Investment and Clinical Activity Accelerate
2026-10-21 · Industry
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →